ALB and neoplasm: In a neoadjuvant trial evaluating camrelizumab combined with albumin-bound paclitaxel and S-1, this regimen significantly improved tumor regression grade and pathological complete response rate in gastric cancer compared to the SOX (S-1 plus oxaliplatin) regimen, without increasing treatment-related adverse events (TRAEs) (10).